Clinical trials: in Mali
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
The purpose of this study is to assess the safety and immunogenicity of the investigational ChAd3-EBO-Z vaccine administered to approximately 3 000 adults in Africa as a single IM dose Considering the risk of exposure to Ebola…
- Trial name
- NCT02485301
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
- Where
- 5 sites in Cameroon, Mali and 2 more
- Volunteers
- 3,024 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria
CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the…
- Trial name
- NCT00371735
- Testing
- chlorproguanil-dapsone-artesunate, chlorproguanil-dapsone
- Where
- 7 sites in Burkina Faso, Ghana and 2 more
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Malaria
Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa
Hypothesis: The MSP3-LSP/Alum vaccine, administered to children will have a protective efficacy of at least 30% (lower bound of confidence interval of 0) against malaria disease occurring during a period beginning from 14 days…
- Trial name
- MSP3-POC (NCT01341704)
- Testing
- MSP3-LSP/AlOH, Verorab Vaccine, 0.9% NaCl/Normal Saline
- Where
- Mali
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Vac4All
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P.
- Trial name
- NCT00677833
- Testing
- Azithromycin plus Chloroquine, Artemether-lumefantrine
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to mefloquine for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
- Trial name
- NCT00082576
- Testing
- Azithromycin/Chloroquine, Mefloquine
- Where
- 6 sites in Ghana, Mali and 2 more
- Volunteers
- 238 people
- Sponsor
- Pfizer
Malaria
ACT MALI: Treatment of Malaria Based on Combination Therapies
Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence…
- Trial name
- NCT00452907
- Testing
- Artesunate, Artesunate + Sulfadoxine-Pyrimethamine, arthemether + lumefantrine
- Where
- Mali
- Volunteers
- 780 people
- Sponsor
- Sanofi
Malaria, Falciparum
Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.
This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.
- Trial name
- NCT00386763
- Testing
- Artemether-lumefantrine
- Where
- 5 sites in Benin, Kenya and 3 more
- Volunteers
- 890 people
- Sponsor
- Novartis
Malaria
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
To compare Azithromycin plus Chloroquine versus Mefloquine to treat uncomplicated plasmodium falciparum malaria.
- Trial name
- NCT00367653
- Testing
- Azithromycin plus Chloroquine, Mefloquine
- Where
- 8 sites in Burkina Faso, Ghana and 4 more
- Volunteers
- 397 people
- Sponsor
- Pfizer
Malaria
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on D28 of administration of Coarsucam™ (artesunate+amodiaquine fixed-dose combination), as a single daily dose, in…
- Trial name
- NCT00316329
- Testing
- Artesunate + Amodiaquine
- Where
- 5 sites in Cameroon, Madagascar and 2 more
- Volunteers
- 1,032 people
- Sponsor
- Sanofi
Plasmodium Falciparum Malaria
Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria
The purpose of this open randomised multi-centre clinical trial is to test the hypothesis that three pills of the fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine, administered over 24 hours is not inferior in…
- Trial name
- NCT00484900
- Testing
- Co-Arinate FDC, Coartem
- Where
- 4 sites in Cameroon, Mali and 2 more
- Volunteers
- 1,390 people
- Sponsor
- Dafra Pharma
Schistosoma Haematobium
Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis
The purpose of this study is to evaluate the efficacy of praziquantel versus As+SMP (Co-Arinate FDC ®) in the treatment of Schistosoma haematobium in 6-15 year old Malian children.
- Trial name
- NCT00510159
- Testing
- Artesunate+Sulfamethoxypyrazine/pyrimethamin, Praziquantel
- Where
- Mali
- Volunteers
- 800 people
- Sponsor
- Dafra Pharma